Overview of chelation recommendations for thalassaemia and sickle cell disease

被引：0
|
作者：
Kaya, Banu [1 ]
机构：
[1] Royal London Hosp, Barts Hlth NHS Trust, London, England
来源：
THALASSEMIA REPORTS | 2014年 / 4卷 / 03期
关键词：
iron toxicity; thalassaemia; sickle cell disease; chelation therapy; drug;
D O I：
10.4081/thal.2014.4860
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The long term consequences of iron toxicity are mostly reversible with effective iron chelation therapy. Recommendations for use of chelation therapy in transfusion dependent thalassaemia (TDT), sickle cell disease (SCD) and non transfusion dependent thalassaemia (NTDT) continue to evolve as our knowledge and clinical experience increases. Improved chelation options including drug combinations and a better understanding of condition specific factors may help to improve efficiency of chelation regimens and meet the needs of patients more effectively.
引用
收藏
页码：3 / 6
页数：4
相关论文
共 50 条
  • [21] An overview on Sickle Cell Disease Profile
    Kaur, M.
    Dangi, C. B. S.
    Singh, M.
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2013, 8 (08): : 70 - 86
  • [22] SICKLE-CELL DISEASE - AN OVERVIEW
    GASTON, MH
    SEMINARS IN ROENTGENOLOGY, 1987, 22 (03) : 150 - 159
  • [23] Haematopoietic stem cell transplantation in β-thalassaemia and sickle cell disease: The Spanish experience
    Alonso, L.
    Gonzalez Vicent, M.
    Belendez, C.
    Elorza, I.
    Badell, I.
    Sastre, A.
    Villa, A.
    Bermudez, M. D. M.
    Diaz de Heredia, C.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S91 - S92
  • [24] Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective
    Vichinsky, Elliott P.
    Ohene-Frempong, Kwaku
    Thein, Swee Lay
    de Castro Lobo, Clarisse Lopes
    Inati, Adlette
    Thompson, Alexis A.
    Smith-Whitley, Kim
    Kwiatkowski, Janet L.
    Swerdlow, Paul S.
    Porter, John B.
    Marks, Peter W.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2011, 28 (02) : 124 - 133
  • [25] Transition in Sickle Cell Disease (SCD) - Recommendations of the German Sickle Cell Disease Transition Initiative
    Boell, J.
    Alashkar, F.
    Aramayo-Singelmann, C.
    Hoferer, A.
    Jarisch, A.
    Kamal, H.
    Oevermann, L.
    Schwarz, M.
    Cario, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 323 - 324
  • [26] Re: Sickle cell disease and beta-thalassaemia major in pregnancy
    Jayadeva, Praveen
    Albertazzi, Paola
    OBSTETRICIAN & GYNAECOLOGIST, 2014, 16 (02): : 143 - 144
  • [27] Fertility and pregnancy in thalassaemia and sickle cell disease. The UK guidelines
    Davis, Bernard
    THALASSEMIA REPORTS, 2014, 4 (03) : 63 - 67
  • [28] The politics of sickle cell and thalassaemia.
    Haarhoff, G
    SOCIOLOGY OF HEALTH & ILLNESS, 2003, 25 (04) : 380 - 381
  • [29] The politics of sickle cell and thalassaemia.
    Walters, J
    JOURNAL OF BIOSOCIAL SCIENCE, 2004, 36 (05) : 627 - 628
  • [30] Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias
    Ho, P. J.
    Tay, L.
    Lindeman, R.
    Catley, L.
    Bowden, D. K.
    INTERNAL MEDICINE JOURNAL, 2011, 41 (07) : 516 - 524
12345